Close Menu

NEW YORK – After changing its name this summer, Helio Health (formerly Laboratory for Advanced Medicine) now aims to validate its circulating tumor DNA (ctDNA)-based hepatocellular carcinoma (HCC) screening assay by comparing it to standard ultrasound screening with the US launch of a multi-center collaboration.

The Irvine, California-based firm also hopes to raise more than $100 million in a funding round by the end of the year to launch its liver test in the US and China in 2021, as well as to further develop assays for colon, breast, and lung cancers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.

Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.

The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.

In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.

Sponsored by
Mission Bio

Recent work by many investigators has discovered that over the course of aging, hematopoietic stem cells (HSCs) commonly undergo clonal expansion.